Integrum announces the appointment of Scott Flora as adjunct board membe

Mölndal, Sweden – May 11, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that Scott Flora has been appointed as an adjunct board member effective immediately. Scott Flora brings vast and extensive competence to the company as Integrum is reinforcing the company’s position as a leader of osseointegrated implant systems.

Scott Flora has over 40 years of experience in strategic and leadership roles in the healthcare sector, particularly in surgical devices, and has held prominent leadership positions at companies including Covidien and Smith & Nephew. He is currently Chairman of the Board at Palliare Ltd and a board member at CytoVeris and New View Surgical. Scott Flora also serves as Strategic Advisor to CareSyntax, MiCarePath, and Integrum. He has previously held several leading positions roles as President and CEO of Invuity (acquired by Stryker), Executive Director of Conventus Orthopaedics, President and CEO of OmniGuide Surgical, President of Covidien's Surgical Device Group, President of Smith& Nephew Orthopedic Reconstruction and General Manager at Smith&Nephew Trauma. Scott Flora has also served on the company boards of Invuity (acquired by Stryker), MAKO Surgical, and Tengion.

“We are excited to have Scott Flora joining our Board as an adjunct board member, prolonging his commitment to the company from his current role as a Strategic advisor. He brings valuable strategic knowledge to the company in eventful times as we are expanding our business around the globe,” said Bengt Sjöholm, chairman of the board at Integrum.

“Integrum is well positioned and has a unique offer driving the innovation of osseointegrated implant systems. I am thrilled to take a seat on the board and hope to bring strategic insights that help strengthen the company´s commercial strategy and grow the market,” said Scott Flora, adjunct board member of Integrum.